Asad Haider
Stock Analyst at Goldman Sachs
(2.76)
# 1,995
Out of 5,093 analysts
13
Total ratings
80%
Success rate
16.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $34.80 | +6.32% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $50.65 | +12.54% | 2 | Dec 2, 2025 | |
| JNJ Johnson & Johnson | Maintains: Buy | $186 → $212 | $199.96 | +6.02% | 2 | Oct 9, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $20.71 | -17.91% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $38.09 | +10.27% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $44.73 | -15.05% | 1 | Sep 12, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $95.85 | +14.76% | 1 | May 29, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $982.22 | -9.59% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $222.99 | -13.00% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $25.33 | -1.30% | 1 | Apr 8, 2025 |
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $34.80
Upside: +6.32%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $50.65
Upside: +12.54%
Johnson & Johnson
Oct 9, 2025
Maintains: Buy
Price Target: $186 → $212
Current: $199.96
Upside: +6.02%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $20.71
Upside: -17.91%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $38.09
Upside: +10.27%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $44.73
Upside: -15.05%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $95.85
Upside: +14.76%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $982.22
Upside: -9.59%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $222.99
Upside: -13.00%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $25.33
Upside: -1.30%